Dana is a Business Developer at the Oncode institute since the start of 2024. For the first year she was based at the Oncode Accelerator, leading project evaluation and due diligence for preclinical and early clinical assets and providing strategic recommendations. Before joining Oncode, she worked as a Business Developer at Cancer Research Horizons, within the University of Birmingham Enterprise, supporting researchers at Universities of Birmingham, Nottingham, Sheffield, York for a period of five years, gaining knowledge and experience in licensing and spinout formation. Her experience at Cancer Research UK prior to transitioning to a business role involved drug development with AstraZeneca during her postdoctoral research at the Cancer Research UK Scotland Centre. Her background is molecular and cellular biology (BSc and MSc at the University of Zagreb), further focusing on cancer biology during her PhD at the University of Strasbourg. She currently supports the Oncode Investigators in all stages of project development and leads on all aspects of valorization strategy and translation activities, aimed at creating impact for patients.